Loading patent…
AssigneesFundacio Privada Institut D'Investigació OncolòGica Vall D'Hebron (Vhio), Fundacio Privada Institucio Catalana De Recerca I Estudis Avancats (Icrea)
InventorsJoan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
Estimating the term…
The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.
A monoclonal antibody or a fragment thereof, which binds full length human Leukemia inhibitory factor (LIF), but does not bind a LIF fragment corresponding to amino acids 1 to 160, wherein the full length human LIF is the precursor to human LIF isoform 1.
The hybridoma cell line deposit number DSM ACC3054, deposited on Apr. 1, 2010 by Vall d'Hebron Institute of Oncology at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.
Dependencies are inferred from the claim text.